| sunitinib / Generic mfg. |
chictr-onc-11001681: targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney |
|
|
| Completed | 4 | 6 | | sunitinib or sorafenib combining with gemcitabine plus cisplatin | peking university cancer hospital institute; Peking University Cancer Hospital and Institute, the program for new century excellent talents in university (985-2-085-113) | the collecting duct carcinoma of kidney | | | | |
2011-006085-40: Evaluation of predictive markers for toxicity and efficacy in patients with metastatic clear cell renal cell carcinoma treated by anti VEGF therapy. |
|
|
| Ongoing | 4 | 90 | Europe | Sutent, Film-coated tablet, Capsule, hard, Votrient, Sutent | Cliniques Universitaires Saint Luc, Pfizer | Metastatic clear cell renal cell carcinoma, Metastatic renal cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-ONRC-12002088: Phase II escalation study of sorafenib in patients with advanced renal cell carcinoma who progressed after routine dosage of sorafenib |
|
|
| Completed | 4 | 140 | | sorafenib 600mg p.o bid ;sunitinib 50mg p.o qd ;Everolimus 10mg p.o qd ;Everolimus 10mg p.o qd | Fudan University Shanghai Cancer Center; Level of the institution：, Fudan University Shanghai Cancer Center | renal cell carcinoma | | | | |
2011-001098-16: STAR: A Randomised Multi-Stage Phase II/III trial of Sunitinib comparing Temporary cessation with Allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced and/or metastatic Renal cancer |
|
|
| Ongoing | 4 | 1000 | Europe | Sunitinib, n/a, Sunitinib (trade name Sutent), Sunitinib (trade name Sutent) | University of Leeds | Metastatic and/or locally advanced Renal Clear Cell Carcinoma | | | | |
|
2012-001415-23: Clinical study to evaluate the effect of sunitinib ans pazopanib blood levels over time and other parameters in patients with kidney cell cancer. |
|
|
| Ongoing | 4 | 100 | Europe | Sutent, Votrient, Sutent, Votrient | Central European Society for Anticancer Drug Research - EWIV, CESAR | Metastasized renal cell carcinoma | | | | |
2012-000425-45: Effect van ochtend- of avondinname van sunitinib op de medicijnspiegels in het bloed |
|
|
| Ongoing | 4 | 18 | Europe | Sunitinib, Midazolam, EU/1/06/347/001-008, PL 29831/0140, Sutent, Dormicum, Sutent, Dormicum | | Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor Niercelcarcinoom, GIST, p-NET | | | | |
ChiCTR-OPC-16008840: The relationship and mechanism of SNPs, AEs and PK in Chinese renal cell carcinoma patients treated with sunitinib |
|
|
| Recruiting | 4 | 50 | | N/A | Department of clinical pharmacology, Affiliated Hospital of Military Medical Science Academy of the PLA of Chinese; Affiliated Hospital of Military Medical Science Academy of the PLA of Chinese, Department of clinical pharmacology, Affiliated Hospital of Military Medical Science Academy of the PLA of Chinese | renal cell carcinoma | | | | |
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie. |
|
|
| Not yet recruiting | 4 | 198 | Europe | Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso | Erasmus MC Cancer Institute, Erasmus MC | Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04] | | | | |
ChiCTR2300068189: Clinical research of efficacy and safety of camrelizumab in the treatment of advanced renal cell carcinoma and advanced malignant melanoma |
|
|
| Recruiting | 4 | 20 | | Camrelizumab combined with sunitinib ;Camrelizumab | Cancer Hospital Affiliated to Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University, Self-funded | Renal carcinoma and malignant melanoma | | | | |
| Not yet recruiting | 4 | 30 | Europe | Olaparib, Lynparza, Lenvatinib, Lenvima, Sunitinib, Sutent, Palbociclib, Ibrance, Pazopanib, Votrient | University Medical Center Groningen | Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma | 03/25 | 03/25 | | |
